NYSEMKT: CANF
Can Fite Biopharma Ltd Stock Ownership - Who owns Can Fite Biopharma?

Insider buying vs selling

Have Can Fite Biopharma Ltd insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when CANF insiders and whales buy or sell their stock.

CANF Shareholders

What type of owners hold Can Fite Biopharma Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Sabby Management LLC1.63%42,559$161.72kInstitution
Citadel Advisors LLC1.30%34,150$129.77kInstitution
Rhumbline Advisers0.80%20,908$79.45kInstitution
Hrt Financial LP0.74%19,383$73.66kInstitution
Virtu Financial LLC0.49%12,908$49.05kInstitution
Citigroup Inc0.21%5,482$20.83kInstitution
Ubs Group Ag0.08%2,152$8.18kInstitution
Osaic Holdings Inc0.02%450$1.71kInstitution
Fifth Third Bancorp0.01%150$570.00Institution
Wells Fargo Company0.00%125$475.00Institution

1 of 2

CANF vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CANF5.28%0.00%
AIM1.21%69.87%Net Buying
EVGN5.10%0.84%
FBLG3.34%96.66%Net Buying
ALZN0.32%99.68%Net BuyingNet Buying

Can Fite Biopharma Stock Ownership FAQ

Who owns Can Fite Biopharma?

Can Fite Biopharma (NYSEMKT: CANF) is owned by 5.28% institutional shareholders, 0.00% Can Fite Biopharma insiders, and 94.72% retail investors. Pnina Fishman is the largest individual Can Fite Biopharma shareholder, owning 88.00 shares representing 0.00% of the company. Pnina Fishman's Can Fite Biopharma shares are currently valued at $306.24.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.